|
|
|
|
||
Re: MEN1309/OBT076MEN1309 is an antibody drug candidate targeted to a cancer antigen highly expressed in multiple blood and solid cancer types, thereby providing multiple potential target indications. The ADC incorporates a fully human antibody generated by Amgen’s Xenomouse® technology and ImmunoGen’s proprietary ADC toxin technology. MEN1309 has very good efficacy in multiple preclinical cancer models and has completed a GLP toxicology study. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
46335 | Re: MEN1309/OBT076 | EFJ61 | 0 | 6/26/2017 9:49:30 AM |